Skip to main content

Adage Capital Management — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

76
Companies
$11.1B
Total invested
$160.5M
Avg. check
22
Industries
Biotechnology 23Therapeutics 13Health Care 12Medical 8Life Science 5Pharmaceutical 4+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 76
Tectonic Therapeutic
February 2025

Tectonic Therapeutic is a biotechnology company which focuses on scientific research in biochemistry and molecular pharmacology.

Biotechnology · Watertown$185.0M Post-IPO Equity
Applied Therapeutics
February 2024

Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.

Biotechnology · New York$100.0M Post-IPO Equity
Energy Vault
February 2026

Energy Vault offers a utility-scale, gravity-based storage solution for renewable energy.

Energy · Lugano$135.5M Post-IPO Debt
Kailera Therapeutics
October 2025

Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.

Biotechnology · Waltham$600.0M Series B
Beckley Psytech
January 2024

Beckley Psytech is a biotechnology company developing psychedelic-based medicines for mental health conditions.

Biotechnology · Beckley$40.0M Undisclosed
Ambros Therapeutics
December 2025

Ambros Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Irvine$125.0M Series A
Ultragenyx Pharmaceutical
November 2025

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

Biotechnology · Novato$400.0M Post-IPO Debt
Aptinyx
November 2022

Aptinyx Inc. is a biopharmaceutical company.

Biopharma · Evanston$5.6M Grant
Antios Therapeutics
November 2021

Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral diseases.

Biopharma · Atlanta$75.0M Series B
Pasithea Therapeutics
November 2025

Pasithea Therapeutics is a biotechnology company that seeks to solve clinical problems such as mental health.

Biotechnology · Miami Beach$60.0M Post-IPO Equity
Cogent Biosciences
November 2025

Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.

Biotechnology · Waltham$200.0M Post-IPO Debt
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Disc Medicine
October 2025

Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders.

Biotechnology · Watertown$225.0M Post-IPO Equity
Scout Bio
October 2021

Scout Bi is a biotechnology company that specializes in veterinary, animal health, and gene therapy.

Biotechnology · Philadelphia$33.0M Series B
Pyramid Biosciences
October 2021

Pyramid Biosciences is a provider of biotechnological services.

Biotechnology · Needham$33.5M Series B
Cerevel Therapeutics
October 2023

Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.

Biotechnology · Boston$450.0M Post-IPO Equity
Equillium
March 2026

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

Biopharma · La Jolla$35.0M Post Ipo Equity
CORXEL Pharmaceuticals
January 2026

CORXEL Pharmaceuticals is a biotechnology company that develops science and medicines for underserved patients.

Biotechnology · Shanghai$287.0M Series D
Century Therapeutics
January 2026

Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.

Biotechnology · Philadelphia$135.0M Post Ipo Equity
Praxis Precision Medicines
January 2026

Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.

Alternative Medicine · Cambridge$575.0M Post Ipo Equity
Annexon Biosciences
November 2025

Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.

Biotechnology · South San Francisco$86.3M Post Ipo Equity
LEXEO Therapeutics
October 2025

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

Biotechnology · New York$154.0M Post Ipo Equity
Spyre Therapeutics
October 2025

Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.

Biotechnology · Sunrise$275.0M Post Ipo Equity
Pepgen
September 2025

PepGen is empowering nucleic acid therapeutics to go the distance.

Biotechnology · Oxford$115.0M Post Ipo Equity

Where Adage Capital Management invests

Biotechnology23
Therapeutics13
Health Care12
Medical8
Life Science5
Pharmaceutical4

About Adage Capital Management's portfolio

How many companies has Adage Capital Management invested in?

Adage Capital Management has invested in 76 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Adage Capital Management invest in?

Adage Capital Management's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 22 different industry categories.

What is Adage Capital Management's largest investment?

Among tracked funding rounds, Kailera Therapeutics received $600.0M in a Series B round. Adage Capital Management's total known invested capital is $11.1B.

What is the average investment size for Adage Capital Management?

Adage Capital Management's average investment size is $160.5M across its portfolio of 76 companies.

What are Adage Capital Management's most recent investments?

Recent Adage Capital Management portfolio additions include Tectonic Therapeutic, Applied Therapeutics, Energy Vault, Kailera Therapeutics, Beckley Psytech. These companies were founded in 2020 or later.

Reach the founders behind these 76 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →